Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement
详细信息 查看全文
- 作者：Seung-Hye Lee1 ; 3 ; Claire E. Le Pichon1 ; 3 ; 4 ; Oskar Adolfsson2 ; Valé ; rie Gafner2 ; Maria Pihlgren2 ; Han Lin1 ; Hilda Solanoy1 ; Robert Brendza1 ; Hai Ngu1 ; Oded Foreman1 ; Ruby Chan1 ; 5 ; James A. Ernst1 ; Danielle DiCara1 ; Isidro Hotzel1 ; Karpagam Srinivasan1 ; David V. Hansen1 ; Jasvinder Atwal1 ; Yanmei Lu1 ; Daniela Bumbaca1 ; Andrea Pfeifer2 ; Ryan J. Watts1 ; Andreas Muhs2 ; andreas.muhs@acimmune.com" class="auth_mail" title="E-mail the corresponding author ; Kimberly Scearce-Levie1 ; kscearcelevie@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Gai Ayalon1 ; ayalon.gai@gene.com" class="auth_mail" title="E-mail the corresponding author
- 刊名：Cell Reports
- 出版年：2016
- 出版时间：9 August 2016
- 年：2016
- 卷：16
- 期：6
- 页码：1690-1700
- 全文大小：3922 K
文摘
- •
Antibody effector function and microglia engagement are not required for targeting tau
- •
Full effector and effectorless tau antibodies slow the spread of tau pathology in vivo
- •
Only effectorless anti-tau protects neurons from toxic tau in the presence of microglia
- •
Anti-tau with reduced effector function may represent a safer approach to targeting tau